The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
Authors:
Open Access
- 30 December 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0227120
Abstract
Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large scale study of a population of MS women is therefore warranted. To assess whether, among those born to women with MS, infants prenatally exposed to IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally exposed to any MS disease modifying drugs. Swedish and Finnish register data was used. Births to women with MS in Sweden and Finland between 2005–2014 for which a birth measurement for weight, height, and head circumference was available were included. The exposure window was from 6 months prior to LMP to the end of pregnancy. In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure window, and 835 pregnancies were counted as unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331 respectively. Infants prenatally exposed to interferon-beta were on average 28 grams heavier (p = 0.17), 0.01 cm longer (p = 0.95), and had head circumferences 0.14 cm larger (p = 0.13) in Sweden. In Finland, infants were 50 grams lighter (p = 0.27), 0.02 cm shorter (p = 0.92) and had head circumferences 0.22 cm smaller (p = 0.15) relative to those unexposed. This study provides evidence that exposure to IFN-beta during pregnancy does not influence birth weight, length, or head circumference.Keywords
Funding Information
- Bayer AG
- Biogen
- Merck KGaA
- Novartis Pharma AG
This publication has 26 references indexed in Scilit:
- Multiple sclerosis and pregnancy in the 'treatment era'Nature Reviews Neurology, 2015
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosisMultiple Sclerosis and Related Disorders, 2014
- Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapyMultiple Sclerosis Journal, 2011
- Maternal age, education level and migration: Socioeconomic determinants for smoking during pregnancy in a field study from TurkeyBMC Public Health, 2010
- Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational studyMultiple Sclerosis Journal, 2009
- Influence of maternal and social factors as predictors of low birth weight in ItalyBMC Public Health, 2007
- The reproductive effects of beta interferon therapy in pregnancyNeurology, 2005
- Assessing the net effect of young maternal age on birthweightAmerican Journal of Human Biology, 2003
- Fetal origins of coronary heart diseaseBMJ, 1995